Lv5
1170 积分 2020-11-13 加入
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
7小时前
求助中
Immunotherapy Complications
29天前
已关闭
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
2个月前
已完结
Optimization of Immunotherapy-Based Combinations for Metastatic Renal Cell Carcinoma: A Network Meta-Analysis
2个月前
已完结
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial
2个月前
已完结
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial
3个月前
已完结
Extended survival of a patient with gastrointestinal multiple malignancies managed with anti-PD-1 immunotherapy: a case report
3个月前
已完结
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial
3个月前
已完结
Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial
5个月前
已完结
Small Molecule–Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment
5个月前
已完结
皖公网安备34019202002308
